ArticleBiochemical and biophysical research communications2011

The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).

Joanna Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.